COVID-19 infection: viral macro-and micro-vascular coagulopathy and thromboembolism/prophylactic and therapeutic management
AS Manolis, TA Manolis, AA Manolis… - Journal of …, 2021 - journals.sagepub.com
Coronavirus-2019 (COVID-19) predisposes patients to arterial and venous thrombosis
commonly complicating the clinical course of hospitalized patients and attributed to the …
commonly complicating the clinical course of hospitalized patients and attributed to the …
Increased susceptibility for thromboembolic events versus high bleeding risk associated with COVID-19
C Tudoran, DE Velimirovici, DM Berceanu-Vaduva… - Microorganisms, 2022 - mdpi.com
The infection with the SARS-CoV-2 virus is associated with numerous systemic
involvements. Besides the severe respiratory injuries and cardiovascular complications, it …
involvements. Besides the severe respiratory injuries and cardiovascular complications, it …
[HTML][HTML] Circulating exosomes are strongly involved in SARS-CoV-2 infection
Knowledge of the host response to the novel coronavirus SARS-CoV-2 remains limited,
hindering the understanding of COVID-19 pathogenesis and the development of therapeutic …
hindering the understanding of COVID-19 pathogenesis and the development of therapeutic …
[HTML][HTML] Cardiac manifestations of coronavirus (COVID-19)
I Basu-Ray, A Adeboye, MP Soos - StatPearls [Internet], 2023 - ncbi.nlm.nih.gov
Cardiac Manifestations of Coronavirus (COVID-19) - StatPearls - NCBI Bookshelf US flag An
official website of the United States government Here's how you know NIH NLM Logo Access …
official website of the United States government Here's how you know NIH NLM Logo Access …
[HTML][HTML] COVID‐19 patients often show high‐titer non‐platelet‐activating anti‐PF4/heparin IgG antibodies
Background Heparin‐induced thrombocytopenia (HIT) is a severe adverse reaction to
heparin caused by heparin‐dependent, platelet‐activating anti‐platelet factor 4 …
heparin caused by heparin‐dependent, platelet‐activating anti‐platelet factor 4 …
[HTML][HTML] Factores de riesgo asociados a mortalidad en pacientes adultos con neumonía por SARS-CoV-2 en un hospital público de Lima, Perú
MJM Rodríguez-Zúñiga, A Quintana-Aquehua… - Acta Médica …, 2020 - scielo.org.pe
Resumen RODRIGUEZ-ZUNIGA, Milton JM et al. Factores de riesgo asociados a mortalidad
en pacientes adultos con neumonía por SARS-CoV-2 en un hospital público de Lima, Perú …
en pacientes adultos con neumonía por SARS-CoV-2 en un hospital público de Lima, Perú …
Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: prospective results from a multi-center study
F Rashidi, S Barco, F Kamangar, GA Heresi… - Thrombosis research, 2021 - Elsevier
Background Thrombosis and pulmonary embolism appear to be major causes of mortality in
hospitalized coronavirus disease 2019 (COVID-19) patients. However, few studies have …
hospitalized coronavirus disease 2019 (COVID-19) patients. However, few studies have …
Coronavirus disease 2019: clinics, treatment, and prevention
FR Burkert, L Lanser, R Bellmann-Weiler… - Frontiers in …, 2021 - frontiersin.org
The coronavirus disease 2019 (COVID-19) pandemic, caused by a novel severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged at the end of 2019 in China …
respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged at the end of 2019 in China …
[HTML][HTML] Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID‐19: The Swiss COVID‐HEP randomized clinical trial
M Blondon, S Cereghetti, J Pugin, C Marti… - Research and Practice …, 2022 - Elsevier
Background Hospitalized patients with COVID‐19 suffered initially from high rates of venous
thromboembolism (VTE), with possible associations between therapeutic anticoagulation …
thromboembolism (VTE), with possible associations between therapeutic anticoagulation …
Intracerebral hemorrhage in COVID-19 patients with pulmonary failure: a propensity score-matched registry study
CN Lang, JS Dettinger, M Berchtold-Herz, S Utzolino… - Neurocritical care, 2021 - Springer
Abstract Background Hypercoagulability in Coronavirus Disease 2019 (COVID-19) causes
deep vein thrombosis and pulmonary embolism necessitating systemic anticoagulation …
deep vein thrombosis and pulmonary embolism necessitating systemic anticoagulation …